Gracell Biotechnologies (Gracell Biotechnologies) ROCE % : -18.51% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gracell Biotechnologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gracell Biotechnologies's annualized ROCE % for the quarter that ended in Sep. 2023 was -18.51%.

Gracell Biotechnologies ROCE % Historical Data

The historical data trend for Gracell Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gracell Biotechnologies ROCE % Chart

Gracell Biotechnologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

-43.09

-51.57

-33.86

-32.44

-34.13

Gracell Biotechnologies Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial													-40.55	-34.18	-44.78	-46.55	-18.51

Gracell Biotechnologies ROCE % Calculation

Gracell Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-86.17	/	( ( (323.448 - 24.355)	+	(237.571 - 31.648) )	/ 2 )
	=	-86.17	/	( (299.093	+	205.923)	/ 2 )
	=	-86.17	/	252.508
	=	-34.13 %

Gracell Biotechnologies's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-36.352	/	( ( (192.405 - 27.064)	+	(258.973 - 31.444) )	/ 2 )
	=	-36.352	/	( ( 165.341	+	227.529 )	/ 2 )
	=	-36.352	/	196.435
	=	-18.51 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Gracell Biotechnologies (NAS:GRCL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gracell Biotechnologies ROCE % Related Terms

Thank you for viewing the detailed overview of Gracell Biotechnologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gracell Biotechnologies (Gracell Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gracell Biotechnologies Inc (NAS:GRCL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

218 Sangtian Street, Building 12, Block B, Phase II, Biobay Industrial Park, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.gracellbio.com

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.